Rhumbline Advisers increased its holdings in Cryolife Inc (NYSE:CRY) by 9.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,599 shares of the medical equipment provider’s stock after purchasing an additional 5,308 shares during the quarter. Rhumbline Advisers owned approximately 0.19% of Cryolife worth $1,421,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of CRY. Teachers Advisors LLC grew its stake in shares of Cryolife by 2.6% in the first quarter. Teachers Advisors LLC now owns 53,065 shares of the medical equipment provider’s stock worth $884,000 after purchasing an additional 1,345 shares during the last quarter. Vanguard Group Inc. boosted its position in Cryolife by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,556,106 shares of the medical equipment provider’s stock valued at $25,909,000 after acquiring an additional 43,212 shares in the last quarter. Geode Capital Management LLC boosted its position in Cryolife by 2.9% during the 1st quarter. Geode Capital Management LLC now owns 207,318 shares of the medical equipment provider’s stock valued at $3,451,000 after acquiring an additional 5,931 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Cryolife by 5.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 114,544 shares of the medical equipment provider’s stock valued at $1,908,000 after acquiring an additional 5,985 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Cryolife by 59.4% during the 1st quarter. Bank of America Corp DE now owns 91,155 shares of the medical equipment provider’s stock valued at $1,517,000 after acquiring an additional 33,957 shares in the last quarter. 73.31% of the stock is currently owned by institutional investors.

In other news, CAO Amy Horton sold 4,000 shares of Cryolife stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total transaction of $76,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 98,705 shares in the company, valued at $1,875,395. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James Benson sold 2,000 shares of Cryolife stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $22.80, for a total transaction of $45,600.00. The disclosure for this sale can be found here. Insiders have sold 60,190 shares of company stock valued at $1,163,840 over the last quarter. Company insiders own 6.00% of the company’s stock.

CRY has been the topic of several research reports. Canaccord Genuity reaffirmed a “buy” rating and set a $25.00 price objective on shares of Cryolife in a research report on Monday, October 9th. Northland Securities reaffirmed a “buy” rating and set a $23.50 price objective on shares of Cryolife in a research report on Monday, November 13th. TheStreet cut Cryolife from a “b” rating to a “c+” rating in a research report on Monday, October 30th. Zacks Investment Research cut Cryolife from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Finally, Lake Street Capital lifted their price objective on Cryolife to $26.00 and gave the company a “buy” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $23.63.

Shares of Cryolife Inc (NYSE:CRY) opened at $19.30 on Thursday. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $637.37, a P/E ratio of 46.46 and a beta of 0.81. Cryolife Inc has a 12-month low of $14.02 and a 12-month high of $24.00.

Cryolife (NYSE:CRY) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.08. Cryolife had a return on equity of 6.43% and a net margin of 5.28%. The business had revenue of $44.00 million for the quarter, compared to analysts’ expectations of $44.60 million. During the same period in the previous year, the firm posted $0.13 EPS. The business’s revenue was down 2.9% on a year-over-year basis. equities research analysts anticipate that Cryolife Inc will post 0.28 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Cryolife Inc (CRY) Position Increased by Rhumbline Advisers” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/14/cryolife-inc-cry-position-increased-by-rhumbline-advisers.html.

Cryolife Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Stock Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related stocks with our FREE daily email newsletter.